Aurore Palmaro1,2,3, Marie-Eve Rougé-Bugat2,4, Martin Gauthier5, Fabien Despas1,2,3, Guillaume Moulis1,2,3,6, Maryse Lapeyre-Mestre1,2,3. 1. Medical and Clinical Pharmacology department, Toulouse University Hospital, Toulouse, France. 2. UMR INSERM 1027, University of Toulouse, Toulouse, France. 3. CIC 1436, Toulouse University Hospital, Toulouse, France. 4. Academic Department of Family Medicine, Faculty of Medicine Toulouse, University of Toulouse, Toulouse, France. 5. Department of Haematology, Toulouse University Hospital, Toulouse, France. 6. Department of Internal Medicine, Toulouse University Hospital, Toulouse, France.
Abstract
PURPOSE: The risk of venous thromboembolic event (VTE) in multiple myeloma is particularly increased. Current guidelines recommend systematic VTE prophylaxis with vitamin K antagonists (VKA) or low weight molecular heparin (LWMH) or unfractionated heparin (UFH) in high-risk patients, based on treatment received [e.g. use of IMiDs (thalidomide, lenalidomide and pomalidomide), alkylating agents or erythropoietin] and individual risk factors (e.g. history of VTE). The aim of this study was to describe strategy of VTE prophylaxis and prescribing of other antithrombotic agents during the first 6 months of multiple myeloma therapy, with stratification on IMiD-based regimens and drug and disease-related risk factors. METHODS: A retrospective cohort study of French beneficiaries from the health insurance database (SNIIRAM, Système National d'Information Inter-Régime de l'Assurance Maladie) was designed in the Midi-Pyrénées area (South West France). Patients starting a treatment for multiple myeloma in the period 2011-2014 were identified through hospital and chronic disease diagnoses. RESULTS: Among the 236 incident multiple myeloma patients, 56% male (n = 133), 67% >65 years (n = 159) and 47% (n = 110) patients received an IMiD-based regimen. In these patients, 63% (n = 69) were identified as high-risk patients with indication for low molecular weight heparin or equivalent, and 37% (n = 41) were identified as low-risk with aspirin recommended. Among the high-risk IMiDs patients, 43% (30/69) currently received a VTE prophylaxis after starting their first regimen: 70% LWMH (21/30), 40% VKA (12/30), 10% UFH (3/30) and 13% (4/30) other drugs (rivaroxaban and fondaparinux); 33% of the patients (23/69) received an antiplatelet drug only, and 23% (16/69) did not receive any antithrombotic drug. CONCLUSIONS: These results revealed lack of implementation of VTE prophylaxis in one out of high-risk multiple myeloma patients with IMiD.
PURPOSE: The risk of venous thromboembolic event (VTE) in multiple myeloma is particularly increased. Current guidelines recommend systematic VTE prophylaxis with vitamin K antagonists (VKA) or low weight molecular heparin (LWMH) or unfractionated heparin (UFH) in high-risk patients, based on treatment received [e.g. use of IMiDs (thalidomide, lenalidomide and pomalidomide), alkylating agents or erythropoietin] and individual risk factors (e.g. history of VTE). The aim of this study was to describe strategy of VTE prophylaxis and prescribing of other antithrombotic agents during the first 6 months of multiple myeloma therapy, with stratification on IMiD-based regimens and drug and disease-related risk factors. METHODS: A retrospective cohort study of French beneficiaries from the health insurance database (SNIIRAM, Système National d'Information Inter-Régime de l'Assurance Maladie) was designed in the Midi-Pyrénées area (South West France). Patients starting a treatment for multiple myeloma in the period 2011-2014 were identified through hospital and chronic disease diagnoses. RESULTS: Among the 236 incident multiple myelomapatients, 56% male (n = 133), 67% >65 years (n = 159) and 47% (n = 110) patients received an IMiD-based regimen. In these patients, 63% (n = 69) were identified as high-risk patients with indication for low molecular weight heparin or equivalent, and 37% (n = 41) were identified as low-risk with aspirin recommended. Among the high-risk IMiDs patients, 43% (30/69) currently received a VTE prophylaxis after starting their first regimen: 70% LWMH (21/30), 40% VKA (12/30), 10% UFH (3/30) and 13% (4/30) other drugs (rivaroxaban and fondaparinux); 33% of the patients (23/69) received an antiplatelet drug only, and 23% (16/69) did not receive any antithrombotic drug. CONCLUSIONS: These results revealed lack of implementation of VTE prophylaxis in one out of high-risk multiple myelomapatients with IMiD.
Authors: Ang Li; Qian Wu; Suhong Luo; Greg S Warnick; Neil A Zakai; Edward N Libby; Brian F Gage; David A Garcia; Gary H Lyman; Kristen M Sanfilippo Journal: J Natl Compr Canc Netw Date: 2019-07-01 Impact factor: 11.908
Authors: C Rioufol; F Ranchon; V Leclerc; L Karlin; C Herledan; L Marchal; A Baudouin; A Gouraud; A G Caffin; V Larbre; A Lazareth; E Bachy; G Salles; H Ghesquières Journal: J Cancer Res Clin Oncol Date: 2021-06-18 Impact factor: 4.553